MBX Biosciences, Inc. (MBX)
66.76
-1.86
(-2.71%)
USD |
NASDAQ |
Aug 26, 16:00
66.74
-0.02
(-0.02%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.201B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 334.4% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 7.816 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0082 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN. |
| URL | http://www.mbxbio.com |
| Investor Relations URL | https://mbxbio.com/investors/ |
| HQ State/Province | Indiana |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN. |
| URL | http://www.mbxbio.com |
| Investor Relations URL | https://mbxbio.com/investors/ |
| HQ State/Province | Indiana |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 05, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |